577 related articles for article (PubMed ID: 11469927)
41. Hormonal interventions to prevent hormonal cancers: breast and prostate cancers.
Dunn BK; Ford LG
Eur J Cancer Prev; 2007 Jun; 16(3):232-42. PubMed ID: 17415094
[TBL] [Abstract][Full Text] [Related]
42. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force.
Nelson HD; Smith ME; Griffin JC; Fu R
Ann Intern Med; 2013 Apr; 158(8):604-14. PubMed ID: 23588749
[TBL] [Abstract][Full Text] [Related]
43. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
Fisher B; Costantino JP; Wickerham DL; Redmond CK; Kavanah M; Cronin WM; Vogel V; Robidoux A; Dimitrov N; Atkins J; Daly M; Wieand S; Tan-Chiu E; Ford L; Wolmark N
J Natl Cancer Inst; 1998 Sep; 90(18):1371-88. PubMed ID: 9747868
[TBL] [Abstract][Full Text] [Related]
44. Raloxifene and the prevention of breast cancer.
Bevers TB
Expert Opin Pharmacother; 2006 Nov; 7(16):2301-7. PubMed ID: 17059385
[TBL] [Abstract][Full Text] [Related]
45. The effect of SERMs on the endometrium.
Goldstein SR
Ann N Y Acad Sci; 2001 Dec; 949():237-42. PubMed ID: 11795358
[TBL] [Abstract][Full Text] [Related]
46. Managing the risk of invasive breast cancer in women at risk for breast cancer and osteoporosis: the role of raloxifene.
Vogel VG
Clin Interv Aging; 2008; 3(4):601-9. PubMed ID: 19281053
[TBL] [Abstract][Full Text] [Related]
47. Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk.
Grady D; Cauley JA; Geiger MJ; Kornitzer M; Mosca L; Collins P; Wenger NK; Song J; Mershon J; Barrett-Connor E;
J Natl Cancer Inst; 2008 Jun; 100(12):854-61. PubMed ID: 18544744
[TBL] [Abstract][Full Text] [Related]
48. Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Nelson HD; Fu R; Zakher B; Pappas M; McDonagh M
JAMA; 2019 Sep; 322(9):868-886. PubMed ID: 31479143
[TBL] [Abstract][Full Text] [Related]
49. SERMs for the treatment and prevention of breast cancer.
Swaby RF; Sharma CG; Jordan VC
Rev Endocr Metab Disord; 2007 Sep; 8(3):229-39. PubMed ID: 17440819
[TBL] [Abstract][Full Text] [Related]
50. Update on raloxifene to prevent endometrial-breast cancer.
Goldstein SR
Eur J Cancer; 2000 Sep; 36 Suppl 4():S54-6. PubMed ID: 11056320
[TBL] [Abstract][Full Text] [Related]
51. Raloxifene: a review of its use in the prevention of invasive breast cancer.
Moen MD; Keating GM
Drugs; 2008; 68(14):2059-83. PubMed ID: 18778124
[TBL] [Abstract][Full Text] [Related]
52. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
53. Effects of high dose raloxifene in selected patients with advanced breast carcinoma.
Gradishar W; Glusman J; Lu Y; Vogel C; Cohen FJ; Sledge GW
Cancer; 2000 May; 88(9):2047-53. PubMed ID: 10813716
[TBL] [Abstract][Full Text] [Related]
54. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis.
Cranney A; Adachi JD
Drug Saf; 2005; 28(8):721-30. PubMed ID: 16048357
[TBL] [Abstract][Full Text] [Related]
55. The endocrine prevention of breast cancer.
Howell A
Best Pract Res Clin Endocrinol Metab; 2008 Aug; 22(4):615-23. PubMed ID: 18971122
[TBL] [Abstract][Full Text] [Related]
56. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.
Jordan VC; Gapstur S; Morrow M
J Natl Cancer Inst; 2001 Oct; 93(19):1449-57. PubMed ID: 11584060
[TBL] [Abstract][Full Text] [Related]
57. Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR).
Runowicz CD; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Ford LG; Vogel VG; Wolmark N
Am J Obstet Gynecol; 2011 Dec; 205(6):535.e1-5. PubMed ID: 21872200
[TBL] [Abstract][Full Text] [Related]
58. Chemoprevention with antiestrogens: the beginning of the end for breast cancer. Daniel G. Miller Lecture.
Jordan VC
Ann N Y Acad Sci; 2001 Dec; 952():60-72. PubMed ID: 11795444
[TBL] [Abstract][Full Text] [Related]
59. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women.
Veronesi U; Maisonneuve P; Rotmensz N; Costa A; Sacchini V; Travaglini R; D'Aiuto G; Lovison F; Gucciardo G; Muraca MG; Pizzichetta MA; Conforti S; Decensi A; Robertson C; Boyle P;
J Natl Cancer Inst; 2003 Jan; 95(2):160-5. PubMed ID: 12529349
[TBL] [Abstract][Full Text] [Related]
60. Tamoxifen: catalyst for the change to targeted therapy.
Jordan VC
Eur J Cancer; 2008 Jan; 44(1):30-8. PubMed ID: 18068350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
